Mometasone Furoate for COPD Treatment
Author Information
Author(s): Peter M A Calverley, Stephen Rennard, Harold S Nelson, Jill P Karpel, Eduardo H Abbate, Paul Stryszak, Heribert Staudinger
Primary Institution: Department of Medicine, University Hospital Aintree, Liverpool, UK
Hypothesis
Mometasone furoate administered once daily in the evening would be statistically superior to placebo for changes from baseline in postbronchodilator FEV1 and total COPD symptoms.
Conclusion
Once-daily mometasone furoate improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to twice-daily dosing.
Supporting Evidence
- Mometasone furoate significantly increased postbronchodilator FEV1 from baseline.
- The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group.
- Health status improved significantly in all domains in the pooled MF-DPI groups versus placebo.
Takeaway
This study shows that taking mometasone furoate once a day helps people with breathing problems feel better and breathe easier, just like taking it twice a day.
Methodology
A 52-week, randomized, double-blind, placebo-controlled study with 911 subjects comparing mometasone furoate 800 μg once daily, 400 μg twice daily, and placebo.
Potential Biases
Potential bias due to the exclusion of subjects with a history of asthma or significant medical illnesses other than COPD.
Limitations
The study duration was only one year, and the results may not apply to all COPD patients.
Participant Demographics
Mean age was 65 years, 38% were females, and 62% were males.
Statistical Information
P-Value
P < 0.001
Confidence Interval
95% CI for FEV1 changes: 0.063 (0.033–0.094) for 800 μg QD PM and 0.075 (0.044–0.105) for 400 μg BID.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website